WINTON GROUP Ltd Grows Stock Holdings in Natera, Inc. $NTRA

WINTON GROUP Ltd grew its position in shares of Natera, Inc. (NASDAQ:NTRA) by 112.1% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 7,000 shares of the medical research company’s stock after purchasing an additional 3,700 shares during the period. WINTON GROUP Ltd’s holdings in Natera were worth $1,127,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Dynamic Technology Lab Private Ltd purchased a new position in shares of Natera during the 3rd quarter valued at about $1,593,000. Blair William & Co. IL boosted its stake in Natera by 110.4% in the third quarter. Blair William & Co. IL now owns 5,716 shares of the medical research company’s stock worth $920,000 after buying an additional 2,999 shares in the last quarter. HUB Investment Partners LLC bought a new position in Natera during the third quarter valued at approximately $265,000. Neuberger Berman Group LLC grew its position in Natera by 14.0% during the third quarter. Neuberger Berman Group LLC now owns 188,480 shares of the medical research company’s stock valued at $30,340,000 after acquiring an additional 23,128 shares during the last quarter. Finally, Aptus Capital Advisors LLC purchased a new position in shares of Natera during the third quarter worth approximately $213,000. 99.90% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity

In other Natera news, CFO Michael Burkes Brophy sold 785 shares of the business’s stock in a transaction dated Tuesday, March 10th. The shares were sold at an average price of $204.13, for a total value of $160,242.05. Following the transaction, the chief financial officer owned 63,354 shares in the company, valued at approximately $12,932,452.02. The trade was a 1.22% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Solomon Moshkevich sold 915 shares of the company’s stock in a transaction dated Tuesday, March 10th. The shares were sold at an average price of $204.13, for a total transaction of $186,778.95. Following the transaction, the insider directly owned 150,882 shares of the company’s stock, valued at approximately $30,799,542.66. This trade represents a 0.60% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 371,333 shares of company stock worth $86,162,243 in the last quarter. Insiders own 5.63% of the company’s stock.

Analyst Ratings Changes

NTRA has been the subject of a number of recent research reports. Zacks Research upgraded shares of Natera from a “strong sell” rating to a “hold” rating in a report on Thursday, January 1st. BTIG Research increased their target price on shares of Natera from $230.00 to $260.00 and gave the company a “buy” rating in a report on Friday, December 5th. UBS Group lifted their target price on shares of Natera from $218.00 to $280.00 and gave the stock a “buy” rating in a research report on Tuesday, November 18th. Stephens boosted their price target on shares of Natera from $197.00 to $235.00 and gave the stock an “overweight” rating in a research note on Thursday, November 13th. Finally, Guggenheim upped their price target on shares of Natera from $230.00 to $270.00 and gave the company a “buy” rating in a research report on Monday, January 5th. One investment analyst has rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating, three have issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $253.47.

Natera Stock Performance

NASDAQ:NTRA opened at $196.61 on Thursday. The firm has a market cap of $27.87 billion, a PE ratio of -128.50 and a beta of 1.65. Natera, Inc. has a fifty-two week low of $125.38 and a fifty-two week high of $256.36. The business has a 50 day moving average price of $221.32 and a 200-day moving average price of $206.07.

Natera (NASDAQ:NTRA) last issued its earnings results on Thursday, February 26th. The medical research company reported $0.35 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.46) by $0.81. Natera had a negative net margin of 9.03% and a negative return on equity of 15.28%. The firm had revenue of $665.50 million for the quarter, compared to analysts’ expectations of $600.68 million. During the same quarter last year, the business earned ($0.41) earnings per share. Research analysts predict that Natera, Inc. will post -1.49 EPS for the current year.

Natera Profile

Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.

Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.